abstract |
The invention is directed to an antiviral to administer to a mammalian host (e.g., a human) susceptible to paramyxovirus infection, particularly respiratory syncytial virus (RSV) infection. In certain embodiments, a molecule of the antiviral of the invention is a polypeptide, a chemokine polypeptide, a chemokine polypeptide fragment, an organic small molecule or a mimetic peptide, wherein the molecule inhibits or prevents paramyxovirus infection of a mammalian cell. |